-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Maze Therapeutics, Raises Price Target to $110

Benzinga·03/25/2026 15:07:32
Listen to the news
HC Wainwright & Co. analyst Ananda Ghosh maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy and raises the price target from $60 to $110.